Publicaciones en colaboración con investigadores/as de University of Rostock (23)

2024

  1. Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study

    European Journal of Cancer, Vol. 196

  2. Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study

    Brain, Vol. 147, Núm. 8, pp. 2652-2667

2022

  1. Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

    Frontiers in Oncology, Vol. 12

  2. Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients

    European Journal of Cancer, Vol. 166, pp. 185-201

  3. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 28, Núm. 9, pp. 1424-1456

2021

  1. Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel

    Alzheimer's and Dementia, Vol. 17, Núm. 9, pp. 1528-1553

  2. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 14, pp. 1518-1530

2020

  1. Characteristics and treatment regimens across ERS SHARP severe asthma registries

    European Respiratory Journal, Vol. 55, Núm. 1

  2. What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons

    Neurobiology of Aging, Vol. 85, pp. 58-73

2019

  1. First Report of Edge Vascular Response at 12 Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study

    Cardiovascular Revascularization Medicine, Vol. 20, Núm. 5, pp. 392-398

2017

  1. Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts

    CNS Drugs, Vol. 31, Núm. 1, pp. 33-50

  2. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2016

  1. Analysis of plasminogen genetic variants in multiple sclerosis patients

    G3: Genes, Genomes, Genetics, Vol. 6, Núm. 7, pp. 2073-2079

2015

  1. Genome-wide significant association with seven novel multiple sclerosis risk loci

    Journal of Medical Genetics, Vol. 52, Núm. 12, pp. 848-855

2013

  1. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial

    Hepatology, Vol. 57, Núm. 3, pp. 1153-1162

  2. MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis

    Brain, Vol. 136, Núm. 6, pp. 1778-1782

2012

  1. Analysis of the IL28RA locus as genetic risk factor for multiple sclerosis

    Journal of Neuroimmunology, Vol. 245, Núm. 1-2, pp. 98-101

  2. Closing the case of APOE in multiple sclerosis: No association with disease risk in over 29 000 subjects

    Journal of Medical Genetics, Vol. 49, Núm. 9, pp. 558-562

  3. Thoracic Endovascular Aortic Repair (TEVAR) for the treatment of aortic diseases: A position statement from the European Association for Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

    European Heart Journal, Vol. 33, Núm. 13, pp. 1558-1563

  4. Thoracic endovascular aortic repair (TEVAR) for the treatment of aortic diseases: A position statement from the european association for cardio-thoracic surgery (EACTS) and the european society of cardiology (ESC), in collaboration with the european association of percutaneous cardiovascular interventions (EAPCI)

    European Journal of Cardio-thoracic Surgery, Vol. 42, Núm. 1, pp. 17-24